Deepak Bhamidipati appointed as Assistant Director of Drug Development at SCRI
SCRI (Sarah Cannon Research Institute) shared a post on LinkedIn:
”We are thrilled to welcome Dr. Deepak Bhamidipati as our new Assistant Director of Drug Development at Sarah Cannon Research Institute (SCRI)!
Dr. Bhamidipati will also serve as a medical oncologist at SCRI Oncology Partners starting October 22. In his new role, Dr. Bhamidipati will work closely with Vivek Subbiah our Chief of Early-Phase Drug Development, to further enhance our early-phase drug development program in Nashville.
Join us in welcoming Dr. Bhamidipati to SCRI!”
Deepak Bhamidipati is the Assistant Director of Drug Development at the Sarah Cannon Research Institute. He previously completed a Hematology/Oncology Fellowship at MD Anderson Cancer Center and an Internal Medicine Residency at Baylor College of Medicine. During his training, Dr. Bhamidipati developed a clinical and research focus on molecularly targeted therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023